Analysts Set Exagen Inc. (NASDAQ:XGN) Target Price at $14.17

Shares of Exagen Inc. (NASDAQ:XGN) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $14.1667.

Several research analysts have commented on XGN shares. Canaccord Genuity Group lifted their price target on shares of Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. BTIG Research increased their target price on shares of Exagen from $13.00 to $15.00 and gave the company a “buy” rating in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, October 8th. B. Riley restated a “buy” rating and set a $18.00 price target (up from $15.00) on shares of Exagen in a research report on Wednesday, November 5th. Finally, KeyCorp raised their price objective on Exagen from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Tuesday, October 14th.

Hedge Funds Weigh In On Exagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new stake in Exagen in the first quarter valued at approximately $25,000. Larson Financial Group LLC purchased a new position in shares of Exagen in the third quarter worth $105,000. JPMorgan Chase & Co. raised its holdings in Exagen by 320,280.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,019 shares of the company’s stock valued at $176,000 after buying an additional 16,014 shares during the last quarter. XTX Topco Ltd purchased a new stake in Exagen during the 2nd quarter valued at $133,000. Finally, Occudo Quantitative Strategies LP purchased a new stake in Exagen during the 2nd quarter valued at $138,000. 75.25% of the stock is currently owned by institutional investors.

Exagen Trading Down 2.9%

Shares of XGN stock opened at $4.69 on Wednesday. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 1.35. The business has a 50-day moving average price of $6.97 and a two-hundred day moving average price of $8.69. Exagen has a 12-month low of $2.67 and a 12-month high of $12.23. The firm has a market cap of $106.28 million, a P/E ratio of -5.10 and a beta of 1.86.

Exagen (NASDAQ:XGN) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $17.24 million for the quarter, compared to the consensus estimate of $16.90 million. Exagen had a negative net margin of 29.94% and a negative return on equity of 113.48%. Equities analysts anticipate that Exagen will post -0.88 EPS for the current fiscal year.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.